Carnegie Investment Bank is proud to have acted as manager in the exercise of warrants in BerGenBio ASA.
93.6 % of the outstanding warrants were exercised, raising gross proceeds of approximately NOK 139 million.
The net proceeds from the warrants exercise will be used to further advance the company’s strategy for non-small cell lung cancer (“NSCLC”), severe respiratory infections and general corporate purposes and will fund the company’s planned activities into 2H 2025.
Carnegie congratulates BerGenBio on the transaction and are grateful for the vote of confidence.